Номенклатурное обозначение выявленного патогенного варианта при полногеномном секвенировании ДНК
Ген | Ассоциированное заболевание (OMIM) | Изменение ДНК (HG38) (изменение белка) | Зиготность (тип наследования) | Частота (gnomAD v3.1.1) |
GFβ1 | Болезнь Камурати–Энгельмана (131300) | 19:g.41342230G>AENST00000 221930.6:c.652C>T(ENSP0000 0221930.4:p.Arg218Cys илиR218С) | Гетерозигота (доминантный) | 0 |
Авторы: О.С. Кокорина, О.В. Сагайдак, Е.Е. Баранова, Г.Ю. Зобкова, М.С. Беленикин, О.С. Грознова, Л.П. Меликян, О.А. Шидловская
Список литературы
1. Mortier GR, Cohn DH, Cormier-Daire V, et al. Nosology and classification of genetic skeletal disorders: 2019 revision. Am. J. Med. Genet. A. 2019; 179: 2393. DOI: 10.1002/ajmg.a. 61366.
2. Falardeau F, Camurri MV, Campeau PM. Genomic approaches to diagnose rare bone disorders. Bone. 2017; 102: 5. DOI: 10.1016/j.bone.2016.07.020.
3. Kinoshita A, Saito Т, Tomita Н, et al. Domain-specific mutations in TGFB1 result in Camurati–Engelmann disease. Nat. Genet. 2000 Sep; 26 (1): 19–20. DOI: 10.1038/79128.
4. Janssens K, Gershoni-Baruch R, Guañabens N, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta-1 cause Camurati–Engelmann disease. Nat. Genet. 2000 Nov; 26 (3): 273–275. DOI: 10.1038/81563.
5. McGowan NWA, MacPherson H, Janssens K, et al. A mutation affecting the latency-associated peptide of TGFb1 in Camurati–Engelmann disease enhances osteoclast formation in vitro. J. Clin. Endocrinol. Metab. 2003 Jul; 88 (7): 3321–3326. DOI: 10.1210/jc.2002-020564.
6. Kinoshita A, Fukumaki Y, Shirahama S, et al. TGFB1 mutations in four new families with Camurati–Engelmann disease: confirmation of independently arising LAP-domain- specific mutations. Am. J. Med. Genet. A. 2004 May 15; 127A (1): 104–107. DOI: 10.1002/ajmg.a.20671.
7. Camurati M. Di uno raro caso di osteite simmetrica ereditaria degli arti inferiori. Chir. Organi Mov. 1922; 6: 662–665. 8. Engelmann G. Ein Fall von Osteopathia hyperostotica (sclerotisans) multiplex infantilis. Fortschr. Geb. Roentgenstr.Nukl. 1929; 39: 1101–1106.
9. Carlson ML, Beatty CW, Neff BA, et al. Skull base mani-festations of Camurati–Engelmann disease. Arch. Otolaryngol. Head Neck Surg. 2010; 136: 566–575. DOI: 10.1001/ archoto.2010.68.
10. Wallace SE, Lachman RS, Mekikian PB, et al. Marked phenotypic variability in progressive diaphyseal dysplasia (Camurati–Engelmann disease): report of a four-generation pedigree, identification of a mutation in TGFβ1, and review. Am. J. Med. Genet. 2004; 129A: 235–247. DOI: 10.1002/ ajmg.a.30148.
11. Trombetti A, Cortes F, Kaelin A, et al. Intranasal calcitonin reducing bone pain in a patient with Camurati– Engelmann disease. Scand. J. Rheumatol. 2012 Feb; 41 (1): 75–77. DOI: 10.3109/03009742.2011.608195.
12. Ayyavoo A, Derraik JG, Cutfield WS, et al. Elimination of pain and improvement of exercise capacity in Camurati– Engelmann disease with losartan. J. Clin. Endocrinol. Metab. 2014 Nov; 99 (11): 3978–3982. DOI: 10.1210/jc.2014-2025.
13. Simsek-Kiper PO, Dikoglu E, Campos-Xavier B, et al. Positive effects of an angiotensin II type 1 receptor antagonist in Camurati–Engelmann disease: a single case observation. Am. J. Med. Genet. A. 2014 Oct; 164A (10): 2667–2671. DOI: 10.1002/ajmg.a.36692.
14. Inaoka T, Shuke N, Sato J, et al. Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati– Engelmann disease). Clin. Nucl. Med. 2001 Aug; 26 (8): 680– 682. DOI: 10.1097/00003072-200108000-00003.
15. Janssens K, Vanhoenacker F, Bonduelle M, et al. Camurati–Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J. Med. Genet. 2006 Jan; 43 (1): 1–11. DOI: 10.1136/jmg.2005.033522.
16. Демикова Н.С., Асанов А.Ю. Современное состояние, перспективы и роль клинической генетики в педиатрии. Педиатрия им. Г.Н. Сперанского. 2012; 91 (3): 53–58.